Abstract: Background: Nasopharyngeal carcinoma (NPC) is a malignancy arising from nasopharyngeal mucosa that shows squamous differentiation. Data from Global Burden of Cancer (GLOBOCAN) 2018, nasopharyngeal carcinoma has accounts for 129,000 new cases. The high mortality rate indicates that NPC management through surgery, radiotherapy, and chemotherapy have not been satisfactory. Recently, Programmed Death-Ligand 1 (PD-L1) inhibitor has developed as immunotherapy for cancer. High expression of PD-L1 in various types of malignant tumors were associated with poor prognosis.